摘要
目的 观察地奥司明联合塞来昔布治疗急性痛风性关节炎的临床疗效。方法 选取南昌市第一医院收治的90例急性痛风性关节炎患者,随机分为两组:联合用药组(地奥司明联合塞来昔布)与对照组(塞来昔布)各45例。1周后评价两组治疗前后的关节疼痛、肿胀度评分,相关实验室指标变化[C反应蛋白(CRP) 、血沉(ESR)],临床疗效和不良反应。结果 治疗后,联合用药组的关节疼痛、肿胀度评分,CRP水平均低于对照组(P<0.05);两组ESR水平差异无统计学意义(P>0.05)。联合用药组临床有效率为95.56%,高于对照组的88.89%(P<0.05)。两组不良反应差异无统计学意义(P>0.05)。结论 地奥司明联合塞来昔布治疗急性痛风性关节炎安全有效。
Objective To investigate the curative efficacy of diosmin combined with celecoxib in the treatment of acute gouty arthritis(AGA).Methods 90 AGA patients were selected and divided into two groups from The First Hospital of Nanchang,with 45 cases in each group.Diosmin combined with celecoxib were used in the combined group,while celecoxib was used in the control group.After 1 week,the pain index score,joint swelling score,blood biochemical indexes(CRP and ESR)and clinical efficacy of the two groups were evaluated before and after treatment.Results The pain index score,joint swelling score and CRP level in the combined group were lower than those in the control group(P<0.05).While the level of ESR between the two groups after treatment has no statistically difference(P>0.05).The effective rate of combined group(95.56%)was higher than control group(88.89%)(P<0.05).Conclusion Diosmin combined with celecoxib can improve the clinical efficacy in the treatment of AGA without obvious side effects.
作者
王月
陈建兰
林时凡
颜金花
胡凯丽
龙正锡
WANG Yue;CHEN Jianlan;LIN Shifan;YAN Jinhua;HU Kaili;LONG Zhengxi(The First Hospital of Nanchang,The Third Affiliated Hospital of Nanchang University,Nanchang Jiangxi 330008,China)
出处
《药品评价》
CAS
2024年第3期317-319,共3页
Drug Evaluation
基金
江西省卫生健康委科技计划(202211625)。
